As AI proliferates, biopharma companies seek to harness it in clinical trials

For around 20 years, Avi Veidman spent his days in the Israeli intelligence community, analyzing satellite images.

That was until 2017, when he founded a startup called Nucleai. Now, he’s scouring biopsy samples for cancer cells.

Nucleai’s technology is not searching out signs of danger. Instead, the company’s technology maps the proximity of cancer cells, healthy cells, and proteins. Then, it uses artificial intelligence models to identify patterns between those biological elements and historical clinical data to determine which patients are most likely to respond to treatments and should therefore be enrolled in drug companies’ trials.